SBUX — Starbucks Corporation

The sell side is constructive: 28 buy / 28 hold / 3 sell ratings, a $115.50 consensus price target and a $118.80 recent average, following the 2026-07-29 Q3 FY26 beat (comps +7.9%, non-GAAP EPS $0.85, raised full-year EPS guidance) and Brian Niccol's 'the shine is back' framing around ~1,500 store uplifts and a $2B cost program. The tape disagrees: as of 2026-09-13 the stock was -5.48% in a week, -8.99% in a month, -4.17% in three months and -0.41% in six months, an RSI of 31.84, and it sits ~6% under its 20- and 50-day averages - a clear momentum rollover after the big earlier-2026 run. Note the research brief's snapshot ('~$106, near 52-week highs, up 25-30% YTD, 34x forward P/E') is stale relative to the 2026-09-13 price of $98.74, so the market has de-rated the stock by roughly 7% versus that narrative.

This is a cyclical trough-and-recovery, not a structural decline - with one nagging exception. Revenue has gone essentially nowhere over three years ($9.37B in Q4 FY23 to $9.32B in Q3 FY26) but the YoY path is uneven: +5.4% in Q1 FY26 (2025-12-28), +8.8% in Q2 FY26 (2026-03-29), then -1.4% in Q3 FY26 (2026-06-28) - which sits awkwardly against management's +7.9% global comps for that same quarter and needs reconciling at the Q4 print. Margins are the real story: operating margin compressed from 18.2% (Q4 FY23) to a 6.9% trough in Q2 FY25 (2025-03-30), then recovered to 9.9%, 9.9%, 9.2%, 8.2% and 10.5% - the latest quarter is ~60bp above the year-ago 9.9% and the best since Q4 FY24's 11.9%, though still ~770bp below the FY23 peak. Earnings are inflecting off the bottom: TTM diluted EPS of $1.73 versus ~$3.10 GAAP in FY24, with Q4 FY25 ($0.12) and Q1 FY26 ($0.26) gutted by below-the-line charges despite $948M and $910M of operating income, while Q3 FY26 net income of $1,045M / $0.91 EPS was the strongest in eight quarters. Cash is the strongest leg: TTM FCF $3.64B, +62% YoY, aided by capex falling to $291M in Q3 FY26 from $567M a year earlier, and the -2.11% accruals ratio confirms cash earnings are running ahead of reported profit.

Expensive on earnings and EBITDA, roughly fair on sales, with the entire call resting on the margin recovery continuing. As of 2026-09-13: TTM P/E of 56.7x versus a 5-year average of 33.6x; P/S of 2.94x versus a 5-year average of 3.22x; PEG of -2.27x is meaningless because the trailing EPS base is artificially depressed; EV/EBITDA of 22.5x is far above the typical restaurant range, even with operating income running at only ~$3.6B. Forward looks no better - $98.74 / $2.614 FY27E EPS = ~37.8x, and the $115.50 consensus target implies ~44x the same estimate. Only FCF (3.2% TTM yield) and the 2.30% dividend yield look defensible at this price. Negative P/B (-14.7x) and D/E are buyback/negative-equity artifacts rather than distress; net debt of roughly $8.3B against $3.64B TTM FCF is about 2.3x, which is manageable.

At $98.74 the market is pre-paying for the earnings recovery rather than discounting it. Consensus and guidance build in a roughly 50% EPS step-up from TTM $1.73 to $2.614 in FY27, which would still leave the company short of FY24's ~$3.10 GAAP - so the multiple, not the earnings, is the swing factor. When the Q4 FY26 print lands (late October/early November 2026), if comps hold near 7-8% and operating margin clears 11-12%, the stock can justify carrying 35-40x on trough-adjacent EPS; but one quarter of comp deceleration, or another negative reported revenue YoY, likely compresses the multiple toward the high-20s/low-30s, which on $2.61 of EPS is roughly a low-$80s stock. That asymmetry - and the fact that the stock has already fallen ~9% in the month into this print - argues for scaling in rather than buying the whole position at once.

As of 2026-09-13, SBUX was short-term oversold but not washed out: RSI(14) of 31.84, price 6.14% below the 20-day SMA (~$105) and 6.10% below the 50-day (~$105), yet still 0.79% above the 200-day (~$98). Trailing returns were -5.48% (1 week), -8.99% (1 month), -4.17% (3 months) and -0.41% (6 months), meaning the earlier-2026 rally has rolled over and the stock is now sitting on its 200-day rather than near the $110.51 52-week high. Entry-timing implication: an RSI-30 bounce is common, but the 20/50-day cluster near $105 is now overhead resistance - the better risk/reward is either a decisive reclaim of the 50-day or a flush into the low-to-mid $90s, with $77.99 (52-week low) as the level that would signal the turnaround thesis itself is breaking.

• Consumer bifurcation: affluent and upper-middle-class households (SBUX's core) remain resilient and are shielding traffic, but lower-income cohorts are strained, which matters most for the discretionary afternoon daypart and for lower-priced drive-thru competitors taking share there.
• Coffee commodity and input cost volatility - arabica futures, weather in Brazil/Vietnam and any tariff pass-through - feed directly into gross margin and can offset labor and efficiency savings on a lag.
• Wage inflation and US labor dynamics, including store-level unionization activity, raise the fixed cost per store and make the $2B structural cost-reduction program load-bearing for margin recovery rather than optional.
• Rates and balance sheet: ~$11.8B of long-term debt and negative stockholders' equity ($-7.67B) mean refinancing costs and rate expectations affect both interest expense and the multiple the market is willing to pay for a long-duration recovery story.
• China/geopolitics: the reported plan to restructure or divest part of the China footprint with private-equity partners could reshape long-term growth and capital allocation, and is a meaningful swing factor in how the market values the international segment.

• Q4 and full-year FY26 earnings (expected late October/early November 2026) - the decisive test of whether the +7.9% comp is converting into reported revenue dollars (Q3 FY26 revenue was actually -1.4% YoY) and whether FY27 guidance supports the $2.614 consensus EPS.
• Continued execution on the store 'uplift' remodel program (~1,500 completed or underway) and digital menu boards reaching 80-90% of stores, aimed at building afternoon daypart sales.
• Delivery of the $2B cost-savings program, including the recently disclosed ~200 corporate role eliminations and continued pruning of underperforming stores - each incremental dollar drops closer to margin now that revenue growth is slow.
• Progress on the China market restructuring/divestiture with private-equity partners, which could unlock value or reset the international growth algorithm.
• Post-print sell-side target revisions (targets currently range $97-$130, consensus $115.50) and any change to the $0.61 quarterly dividend, which at a 2.30% yield is part of the total-return case.

• Valuation risk is the dominant one: ~37.8x FY27E EPS, 22.5x TTM EV/EBITDA and 56.7x trailing earnings on a company whose latest reported revenue fell 1.4% YoY leaves essentially no cushion for a single disappointing quarter - the deterministic model's own valuation context already labels the stock 'Rich vs. its own history' (30.5/100).
• The comps-to-revenue disconnect: if the +7.9% same-store sales figure is being flattered by mix, licensed-store accounting or lapping weak comparisons while company-operated revenue dollars shrink, the earnings recovery is less real than the headline suggests.
• Balance-sheet and capital-return risk: negative stockholders' equity of $-7.67B, a 0.76 current ratio and $11.8B of long-term debt leave limited flexibility if the turnaround stalls, and buybacks that created the negative equity are hard to sustain without FCF follow-through.
• Competitive intensity in the afternoon daypart from agile, lower-cost drive-thru chains, plus the difficulty of lapping the morning-rush traffic gains once the easiest comparisons roll off.
• Cost and consumer risk: coffee commodity volatility and wage inflation could absorb a large share of the $2B savings program, while any weakening in the affluent consumer - the cohort currently shielding traffic - would hit both comps and the multiple.

The turnaround is real and measurable - operating margin climbed from a 6.9% trough in Q2 FY25 to 10.5% in Q3 FY26, TTM free cash flow rose 62% to $3.64B, and EPS is inflecting off an artificially depressed base with clean accruals - but at $98.74 on 2026-09-13 you are paying ~37.8x FY27E earnings and 22.5x TTM EV/EBITDA for a business whose reported revenue just declined 1.4% YoY, which is why my blended fair value lands near $89 rather than near the $115 consensus target. This is a good business in a genuine recovery at a full price, not a bargain: I would want to accumulate closer to the high-$80s/low-$90s (near or below the 200-day) or after the Q4 FY26 print confirms that comps are converting into revenue and margin, rather than chase a stock that is still 6% below its 20- and 50-day averages with momentum negative.

Equal-weighted blend of three methods as of 2026-09-13: (1) 32x FY2027E EPS of $2.614 = $83.6 - a premium multiple but below the 5-year average trailing P/E of 33.6x, reflecting decelerating reported revenue; (2) 18x FY2027E EBITDA of ~$6.25B (consensus revenue $37.99B at a recovering ~12.5% operating margin plus ~$1.5B of D&A), less ~$8.3B net debt (=$11.78B long-term debt minus $3.45B cash) on ~1.14B shares = ~$91; and (3) a simplified DCF on $3.64B TTM free cash flow growing 10% for five years with a 3% terminal rate and 7.5-8% WACC, which brackets $82-$92 (midpoint ~$87); weighting slightly toward the EBITDA and DCF legs because consensus GAAP EPS appears depressed by restructuring charges gives roughly $89.